

# Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

## NCI-H446

RRID:CVCL\_1562

Type: Cell Line

### Proper Citation

RRID:CVCL\_1562

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1562](https://web.expasy.org/cellosaurus/CVCL_1562)

**Proper Citation:** RRID:CVCL\_1562

**Description:** Cell line NCI-H446 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Lung small cell carcinoma

**Defining Citation:** [PMID:1320893](#), [PMID:1563005](#), [PMID:2985257](#), [PMID:2985258](#), [PMID:6148444](#), [PMID:6713399](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:11030152](#), [PMID:16677475](#), [PMID:17426248](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20193106](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:21163134](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:23716474](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26676926](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28599409](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32351780](#), [PMID:32586373](#), [PMID:35839778](#), [PMID:39154123](#)

**Comments:** Karyotypic information: Hypertriploid karyotype., Population: Caucasian., Part of: MYC genetic alteration cell panel (ATCC TCP-1035)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NCI-H446

**Synonyms:** H446, H-446, NCI-446, NCIH446

**Cross References:** CLO:CLO\_0008088, EFO:EFO\_0002293, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-171, BioGRID\_ORCS\_Cell\_line:806, BioSample:SAMN03473283, BioSample:SAMN10988349, cancercellines:CVCL\_1562, CCRID:1101HUM-PUMC000082, CCRID:3101HUMTCHu196, Cell\_Model\_Passport:SIDM00965, ChEMBL-Cells:ChEMBL3307760, ChEMBL-Targets:ChEMBL612440, CLS:305049, Cosmic:688023, Cosmic:755465, Cosmic:801352, Cosmic:844554, Cosmic:877357, Cosmic:897516, Cosmic:929976, Cosmic:932947, Cosmic:1006526, Cosmic:1021863, Cosmic:1152471, Cosmic:1219102, Cosmic:1239939, Cosmic:1434963, Cosmic:1995578, Cosmic:2125198, Cosmic:2664127, Cosmic:2668272, Cosmic-CLP:688023, DepMap:ACH-000800, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:688023, GEO:GSM169448, GEO:GSM380477, GEO:GSM784254, GEO:GSM845547, GEO:GSM887429, GEO:GSM888509, GEO:GSM1670244, GEO:GSM1682798, GEO:GSM1887892, GEO:GSM1887975, IARC\_TP53:21573, IGRhCellID:NCIH446, KCB:KCB 200688YJ, LiGeA:CCLE\_177, LINCS\_LDP:LCL-1855, PharmacoDB:NCIH446\_1113\_2019, PRIDE:PXD011896, PRIDE:PXD015270, PRIDE:PXD030304, Progenetix:CVCL\_1562, PubChem\_Cell\_line:CVCL\_1562, Wikidata:Q54908054

**ID:** CVCL\_1562

**Record Creation Time:** 20220427T220840+0000

**Record Last Update:** 20260829T234743+0000

---

## Ratings and Alerts

No rating or validation information has been found for NCI-H446.

No alerts have been found for NCI-H446.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 163 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Dutta Chowdhury D, et al. (2026) TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. Molecular cancer therapeutics.

Yoshikawa R, et al. (2026) Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer. International journal of cancer, 158(5), 1336.

Cai G, et al. (2025) UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression. Molecular cell, 85(23), 4347.

Ryan PJ, et al. (2025) ATG4B is required for mTORC1-mediated anabolic activity and is associated with clinical outcomes in non-small cell lung cancer. *FEBS open bio*.

Fu X, et al. (2025) A cancer-specific antigen drives histone acetylation by stabilizing the acetyltransferases. *Cell reports*, 44(10), 116408.

Zhou W, et al. (2025) A public data-based molecular classification of small cell lung cancer by neuroactive signaling networks unveils distinct microenvironment landscapes and immunotherapy-related prognostic biomarkers. *Translational lung cancer research*, 14(11), 4983.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. *iScience*, 28(3), 111943.

Guo Y, et al. (2024) Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents. *Pharmaceutical biology*, 62(1), 233.

Lakhani NJ, et al. (2024) First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(3), 506.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Zhou L, et al. (2024) A novel cancer-germline gene DAZL promotes progression and cisplatin resistance of non-small cell lung cancer by upregulating JAK2 and MCM8. *Gene*, 916, 148449.

Amato L, et al. (2024) Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study. *Cancers*, 16(18).

Kinoshita S, et al. (2024) Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. *Cancer research communications*, 4(3), 723.

Li Y, et al. (2023) A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle. *Journal of translational medicine*, 21(1), 422.

Sparbier CE, et al. (2023) Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes. *Nature cell biology*, 25(2), 258.

Deng L, et al. (2023) Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. *Cell death discovery*, 9(1), 40.

Bryant JD, et al. (2023) Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression. *Molecular therapy oncolytics*, 28, 321.

Cannell IG, et al. (2023) FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy. *Cell reports*, 42(8), 112791.

Duan XH, et al. (2022) HuR affects chemoresistance of small cell lung cancer by regulating FGFR1 expression. *Experimental and therapeutic medicine*, 24(4), 638.